S.Biomedics Co., Ltd. (KOSDAQ:304360)

South Korea flag South Korea · Delayed Price · Currency is KRW
34,600
+150 (0.44%)
At close: Apr 28, 2026
55.51%
Market Cap 426.67B
Revenue (ttm) 16.55B
Net Income (ttm) -8.12B
Shares Out 12.39M
EPS (ttm) -684.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 68,851
Average Volume 85,974
Open 34,750
Previous Close 34,450
Day's Range 34,200 - 35,600
52-Week Range 17,930 - 42,600
Beta 1.53
RSI 61.43
Earnings Date Apr 6, 2026

About S.Biomedics

S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson’s disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2005
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 304360
Full Company Profile

Financial Performance

In 2025, S.Biomedics's revenue was 16.55 billion, an increase of 20.49% compared to the previous year's 13.73 billion. Losses were -8.12 billion, 21.4% more than in 2024.

Financial Statements

News

There is no news available yet.